Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-09-10 Investor Presentation
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于召开2024年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2024 half-year performance explanation meeting (业绩说明会) by 奥锐特药业股份有限公司. It mentions the date, time, location, and format of the meeting, as well as how investors can participate and ask questions. It references that the half-year report was already published on August 29, 2024, and this meeting is to explain and discuss that report. The document does not contain actual financial data or detailed financial statements but is an announcement of an upcoming investor presentation event focused on the half-year results. Therefore, it fits the category of an Investor Presentation (IP) announcement rather than the report itself or a regulatory filing. The document length is short (1456 characters), consistent with an announcement rather than a full report or transcript. Hence, the classification is Investor Presentation (IP) with high confidence.
2024-09-10 Chinese
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the progress of using part of idle raised funds for cash management. It details the amounts, counterparties (banks), investment types (agreed deposits), terms, and risk disclosures. It references prior board approvals and related announcements. The document is a formal public disclosure about the company's cash management activities using idle raised funds, including specifics of contracts and risk controls. It does not contain financial statements, audit opinions, or detailed financial results. It is not a full annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about capital/financing activities related to the use of raised funds for cash management. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-09-02 Chinese
奥锐特药业股份有限公司关于使用募集资金置换预先投入募投项目及已支付发行费用的自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by 奥锐特药业股份有限公司 regarding the use of raised funds to replace previously invested self-raised funds in investment projects and issuance expenses. It details the approval by regulatory authorities, the amount of convertible bonds issued, the use of funds, and the compliance with regulatory requirements. The document includes verification reports from an accounting firm and opinions from the supervisory board and sponsor. It is a formal disclosure about the company's capital management and financing activities related to convertible bonds issuance and fund usage. The document length is 4080 characters, which is relatively short and focused on a specific financing update rather than a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-08-28 Chinese
奥锐特药业股份有限公司关于使用银行承兑汇票支付募投项目资金并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of bank acceptance bills to pay for investment projects funded by proceeds from a convertible bond issuance. It details the approval by the board and supervisory committee, the amount and use of raised funds, and the process for substituting funds. The document is a formal disclosure about the company's capital usage and financing activities related to the convertible bonds. It does not contain financial statements or quarterly/yearly financial results, nor is it a report or presentation. It is an update on financing and capital management activities, specifically about the use of raised funds and substitution with bank acceptance bills. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 2651 characters, which is consistent with an announcement rather than a full report.
2024-08-28 Chinese
奥锐特药业股份有限公司关于使用部分募集资金向全资子公司增资及提供借款以实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the use of part of the raised funds to increase capital and provide loans to a wholly-owned subsidiary for implementing investment projects. It details the approval by the board and supervisory committee, the amount of funds raised, the projects funded, and compliance with regulatory requirements. It is not a full financial report but a specific update on capital usage related to fundraising activities. The document length is 3619 characters, which is relatively short and focused on a capital/financing update rather than a full report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP).
2024-08-28 Chinese
海通证券股份有限公司关于奥锐特药业股份有限公司使用募集资金置换预先投入募投项目及已支付发行费用的自有资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Haitong Securities regarding the use of raised funds by Aoruite Pharmaceutical Co., Ltd. to replace self-raised funds previously invested in projects and paid issuance expenses. It includes specifics about the fundraising amount, project investment plans, pre-investment of self-raised funds, issuance expenses, and compliance with regulatory requirements. The document references regulatory guidelines and includes an auditor's verification report. It is not a full annual or interim financial report, nor is it a simple announcement. It is a specialized audit/verification report related to the use of raised funds and compliance with fundraising regulations. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 4139 characters, which is sufficient for a detailed report rather than a brief announcement. Hence, the classification is AR with high confidence. FY 2024
2024-08-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.